Immune Control gains $11.3M in venture capital

Immune Control of Conshohocken, Pennsylvania, has rounded up $11.3 million in venture capital from BioAdvance Ventures, a venture fund run by Quaker BioVentures, Domain Associates, NewSpring Capital and Anthem Capital. Immune Control says the money will fund two trials of serotonin antagonists as treatments for diseases marked by aberrant immune activation.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.